SCHEMBL13912197

SCHEMBL13912197

CCOC(=O)CS(=O)(=O)c1nc(-c2ccc(F)cc2)cc(C(F)(F)F)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 9/20 1.00
▸ TP53 P04637 8/20 1.00
▸ HPGD P15428 7/20 1.00
▸ ALDH1A1 P00352 7/20 1.00
▸ MAPK1 P28482 6/20 1.00
▸ KMT2A Q03164 6/20 1.00
▸ HSD17B10 Q99714 6/20 1.00
▸ LMNA P02545 6/20 1.00
▸ TLR9 Q9NR96 5/20 1.00
▸ KDM4E B2RXH2 5/20 1.00
▸ HTT P42858 4/20 1.00
▸ BCL2A1 Q16548 2/20 1.00
▸ ALOX15 P16050 1/20 1.00
▸ BID P55957 1/20 1.00
▸ RAB9A P51151 3/20 0.82
▸ MAPT P10636 3/20 0.82
▸ SMN1; SMN2 Q16637 8/20 0.66
▸ STAT1 P42224 5/20 0.66
▸ STAT3 P40763 4/20 0.66
▸ S1PR4 O95977 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13912177 0.90 NPSR1 (1.00) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL19805665 0.76 NPSR1 (1.00) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL20980402 0.73 SDHB (0.58) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL25061922 0.73 KMT2A (0.73) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL19805673 0.71 SDHB (1.00) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL19805710 0.70 SDHB (1.00) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL29976120 0.70 SDHB (1.00) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL19805678 0.68 SDHB (0.80) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL19805686 0.67 SDHB (0.73) NPSR1TP53HPGDALDH1A1MAPK1
SCHEMBL4721292 0.67 SDHB (0.81) NPSR1TP53HPGDALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725508-A1 LIGAND-DRUG CONJUGATE HAVING FREE PAYLOAD RECOVERY UNIT RemeGen Co., Ltd. (CN) 2026-04-15 — — EP claimed
EP-4725508-A1 LIGAND-DRUG CONJUGATE HAVING FREE PAYLOAD RECOVERY UNIT RemeGen Co., Ltd. (CN) 2026-04-15 — — EP disclosed
US-20090069324-A1 CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS THE BURNHAM INSTITUTE (US) 2009-03-12 — — US disclosed
US-20090069324-A1 CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS THE BURNHAM INSTITUTE (US) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069324-A1 CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS TMBIM6, BCL2L1, BCL2L11 NPSR1 4806/4885TP53 204/4885HPGD 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback